Gilead Sciences (GILD) : Wednesdays money flow analysis of Gilead Sciences (GILD) indicates the selling of stock on the strength of price. The investors sold the stock on every rise as seen in the downtick transactions of $26.61 million. In comparison, the inflow of money on upticks was a meager $11.02 million. The dollar value of composite uptick trades minus the downtick trades was negative $15.59 million. The uptick to downtick ratio of 0.41 in the money flow shows weakness. The downtick transaction value was high at $14.01 million, which denotes distribution on strength.. Hence, the net money flow in the stock was negative ($14.01 million). Gilead Sciences (GILD) gained $0.17 at $79.42, a change of 0.21% over the previous days close.
Gilead Sciences Inc. has dropped 3.34% in the last five trading days, however, the shares have posted positive gains of 1.64% in the last 4 weeks. Gilead Sciences Inc. has dropped 3.43% during the last 3-month period . Year-to-Date the stock performance stands at -20.66%.
Gilead Sciences (GILD) : 9 brokerage houses believe that Gilead Sciences (GILD) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 9 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Gilead Sciences (GILD). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 19 Wall Street Analysts endorse the stock as a Buy with a rating of 2.
Gilead Sciences (NASDAQ:GILD): stock was range-bound between the intraday low of $78.51 and the intraday high of $79.5 after having opened at $79.12 on Wednesdays session. The stock finally closed in the red at $79.12, a loss of -0.35%. The stock remained in the red for the whole trading day. The total traded volume was 6,854,055 shares. The stock failed to cross $79.5 in Wednesdays trading. The stocks closing price on Thursday was $79.25.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.